Home>Topics>Companies>Express Scripts

Express Scripts ESRX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Friday Five: Fed Takes the Market's Hand

      Video Reports

      Thu, 21 May 2015

      still think that [TICKER:ESRX] Express Scripts is the best buy in the space right ..... CVS Health merger, we still think Express Scripts will have a great competitive advantage ..... the entire industry. We do think Express Scripts shares still look undervalued. Stipp

      Express Scripts found at 3:22

      costs and improve profitability for these PBMs. Now, we still think that [TICKER:ESRX] Express Scripts is the best buy in the space right now. Even after this [TICKER:CVS] CVS Health merger, we still think Express Scripts will have a great competitive advantage. Actually the consolidation helps them somewhat; it helps keep pricing rational across the entire industry. We do think Express Scripts shares still look undervalued. Stipp: Wal-Mart posted another quarter of same-store sales growth, but profitability was weighed down a bit by investments
    2. Number of Americans using $100,000 in medicines triples - Express Scripts

      Headlines

      Wed, 13 May 2015

      excess of $50,000 in 2014, an increase of 63 percent from the prior year, as doctors prescribed more expensive specialty drugs for diseases such as cancer and hepatitis C, according to an Express Scripts report released on Wednesday.

    3. UPDATE 1- Express Scripts unit to pay $60 mln over Novartis kickbacks, US says

      Headlines

      Fri, 1 May 2015

      NEW YORK, May 1 (Reuters) - U.S. authorities said on Friday that a unit of Express Scripts Holding Co will pay $60 million to resolve claims that it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements.

    4. Express Scripts unit to pay $45 million to U.S. over Novartis kickback scheme

      Headlines

      Fri, 1 May 2015

      NEW YORK, May 1 (Reuters) - A unit of pharmacy benefits manager Express Scripts Holding Co will pay $45 million to resolve U.S. claims it participated in a kickback scheme with Novartis AG to boost...

    5. CVS Produces Strong Top-Line Growth, Offset Once Again by Profit Compression

      Commentary

      Fri, 1 May 2015

      for the quarter increased 11%, which we believe was driven materially by new clients the firm was able to acquire from Express Scripts . From our perspective, CVS performed decently last selling season in taking advantage of its main rival's stumbles

    6. Omnicare draws buyout interest from CVS, Express Scripts - Bloomberg

      Headlines

      Thu, 30 Apr 2015

      April 30 (Reuters) - Pharmacy service provider Omnicare Inc is getting buyout interest from potential buyers, including Express Scripts Holding Co and CVS Health Corp, Bloomberg reported, citing...

    7. PBMs: Health Care's Hidden Gems

      Video Reports

      Thu, 30 Apr 2015

      Caremark, which is a major PBM. We saw Express Scripts (ESRX) acquire Medco. Those were ..... three PBMs before the merger, and now Express Scripts is the largest PBM. Most recently ..... portfolio--I would mostly be looking to Express Scripts , which is, again, the largest company

      Express Scripts found at 1:43, 3:27

      major retail pharmacy, acquire Caremark, which is a major PBM. We saw Express Scripts (ESRX) acquire Medco. Those were two of the top three PBMs before the merger, and now Express Scripts is the largest PBM. Most recently, as you mentioned, [TICKER:UNH] UnitedHealth (UNH) acquiring Catamaran (CTRX)--those were the number-three and number-four players coming together
      our largest holding in the Hare portfolio--I would mostly be looking to Express Scripts , which is, again, the largest company in the industry. It should have some direct benefits from this UnitedHealth-Catamaran merger. For example, Express Scripts has lost clients over the past several years during its integration of Medco; there were some disruptions to customer service, and that caused them to lose some customers--including to Catamaran. Now, the tables have really turned. [TICKER:UNH] UnitedHealth is going to be integrating Catamaran, and that could create some disruption on their side, which could enable Express Scripts to come in and regain some market share that it lost over the last few years. As I said, I think the acquisition really points to the importance of scale within this industry, and nobody has more scale than Express Scripts . They control about 29% of the market today--number one, ahead of [TICKER:UNH] UnitedHealth and also CVS/Caremark. And then there's another aspect of this deal that could be positive for Express Scripts . I always hesitate to speculate on mergers and acquisitions, but it is possible that Express Scripts could be involved in further M&A activity--possibly as a target. Express Scripts is often rumored as a potential target for Walgreens Boots Alliance (WBA). That company has gotten much larger, especially on the distribution side, but some people think that they're lacking a PBM capability to really keep up with CVS, [which is now called] CVS Health. Walgreen is probably the only company that's actually large enough to buy Express Scripts . It's a $60-billion-plus market-cap company, so there aren't a whole lot of suitors out there. But then, even barring a major M&A transaction like that, there are a few smaller PBMs still out there--that other 25% of the market--and they may find it increasingly important that they achieve scale. And Express Scripts would seem to be a very attractive partner for those smaller PBM's, particularly if they don't want to work with [TICKER:UNH] UnitedHealth, which is a competitor to managed-care organizations. For example, Humana (HUM) is another managed-care organization that owns a PBM business. They might not want to outsource that to a competitor in [TICKER:UNH] UnitedHealth. And CVS also comes with its own issues because of the potential conflicts with the retail business. So, Express Scripts is really the only pure-play large-scale independent PBM left, which could make it an attractive partner and possibly lead to value-creating deals with these smaller PBMs that make up the [remaining] 25% of the market that isn't controlled by the big three. Glaser: So, having a stronger number three in place actually improves your confidence in the outlook for Express Scripts ? Coffina: I think so. On one hand, you could say [TICKER:UNH] UnitedHealth will be a somewhat stronger competitor, but I think it's actually more important that the pricing environment within the industry could become a bit more rational. Again, with [TICKER:ESRX] Express Scripts having some near-term opportunities potentially to steal some market share from [TICKER:UNH] UnitedHealth and with the benefits of scale still accruing, I don't see it as a reason to be negative on Express Scripts . If anything, I'd see it as an incremental positive for that company. Glaser: Matt, thanks for your take on this space today.
    8. Amerisource Continues Impressive Results as Firm Delivers a Solid Fiscal 2Q

      Commentary

      Thu, 30 Apr 2015

      implements the highly integrated Walgreen’s contract with great efficiency. The firm also announced it has extended its Express Scripts mail order pharmacy wholesale contract by one year. We find these two developments highly positive and believe they reflect

    9. UPDATE 1- Express Scripts says controlling cancer-drug costs a tough new focus

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.

    10. Express Scripts says controlling cancer-drug costs a tough new focus

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.

    « Prev12345Next »
    Content Partners